Neurogene Inc (NGNE) Stock Price, Quote & News

Company Profile

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LL...

Industry: Biotechnology

Sector: Healthcare

Phone: 855 508 3568

Website: www.neurogene.com

Address:

535 W 24th Street, 5th Floor, New York, United States

Fixer00 Mar. 18 at 2:15 PM

$NGNE cash runway through 1Q 2028 load up on the cheap shares.

0 · Reply

Fixer00 Mar. 17 at 10:51 PM

$NGNE cue ran yesterday. This one runs tomorrow

0 · Reply

runitback349 Mar. 11 at 5:03 PM

$NGNE such low vol. but the chart still is shaping up nicely. Cant buy more than a few hundred shares at a time and have to slowly build a position.

0 · Reply

runitback349 Mar. 9 at 11:18 PM

$NGNE chart looks great. Building higher lows.

0 · Reply

Djohn2012 Mar. 3 at 6:17 PM

$NGNE 100% owned by institutions. Baker Bros holding approximately 1 million shares per Yahoo Finance. Baker Bros are the best!

0 · Reply

Fixer00 Mar. 3 at 6:06 PM

$NGNE and gme is good for the portfolio.

1 · Reply

thefourpercent Mar. 3 at 2:50 PM

$NGNE just a bloody day for the market expectations are still the same here

0 · Reply

thefourpercent Mar. 2 at 8:02 PM

$NGNE holy gold mine of a swing trade AND investment here

0 · Reply

RustyNail911 Feb. 27 at 7:41 PM

$NGNE 200$ Price Target & People Are Selling This Low, Make It Make Sense... 🤦‍♂️

1 · Reply

Panama73 Feb. 27 at 7:08 PM

$CDIO Also like $NGNE

0 · Reply

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

Mar 3, 2026, 4:01 PM EST - 15 days ago

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 26, 2026, 4:01 PM EST - 20 days ago

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

Feb 5, 2026, 7:30 AM EST - 5 weeks ago

Neurogene to Participate in Upcoming Investor Conferences

Feb 4, 2026, 4:01 PM EST - 6 weeks ago

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 7:00 AM EST - 2 months ago

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

Jan 5, 2026, 7:30 AM EST - 2 months ago

Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Nov 24, 2025, 1:32 AM EST - 4 months ago

Neurogene: From Speculation To Execution With NGN-401

Nov 13, 2025, 5:10 PM EST - 4 months ago

Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

Nov 12, 2025, 7:51 PM EST - 4 months ago

Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 12, 2025, 4:01 PM EST - 4 months ago

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

Nov 6, 2025, 7:30 AM EST - 4 months ago

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Oct 9, 2025, 7:00 AM EDT - 5 months ago

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

Oct 8, 2025, 7:30 AM EDT - 5 months ago

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Aug 11, 2025, 4:10 PM EDT - 7 months ago

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

Jul 30, 2025, 11:07 AM EDT - 8 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NTLA QURE RCKT

Jun 30, 2025, 4:01 PM EDT - 9 months ago

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

May 16, 2025, 7:00 AM EDT - 10 months ago

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

May 9, 2025, 7:30 AM EDT - 11 months ago

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

Apr 28, 2025, 5:00 PM EDT - 11 months ago

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

Apr 2, 2025, 4:01 PM EDT - 1 year ago

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Mar 24, 2025, 4:10 PM EDT - 1 year ago

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Feb 24, 2025, 7:30 AM EST - 1 year ago

Neurogene to Participate in Upcoming Conferences

Nov 28, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out

Nov 27, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation

Nov 26, 2024, 10:00 AM EST - 1 year ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Nov 25, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation

Nov 24, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect

Nov 22, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation

Nov 21, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation

Nov 20, 2024, 10:00 AM EST - 1 year ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 18, 2024, 5:25 PM EST - 1 year ago

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Nov 18, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect

Nov 18, 2024, 6:45 AM EST - 1 year ago

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 17, 2024, 10:00 AM EST - 1 year ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 15, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation

Nov 14, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation

Nov 13, 2024, 11:30 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out

Nov 12, 2024, 11:25 AM EST - 1 year ago

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial

Nov 11, 2024, 4:01 PM EST - 1 year ago

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 4, 2024, 7:30 AM EST - 1 year ago

Neurogene Announces Oversubscribed $200 Million Private Placement

Fixer00 Mar. 18 at 2:15 PM

$NGNE cash runway through 1Q 2028 load up on the cheap shares.

0 · Reply

Fixer00 Mar. 17 at 10:51 PM

$NGNE cue ran yesterday. This one runs tomorrow

0 · Reply

runitback349 Mar. 11 at 5:03 PM

$NGNE such low vol. but the chart still is shaping up nicely. Cant buy more than a few hundred shares at a time and have to slowly build a position.

0 · Reply

runitback349 Mar. 9 at 11:18 PM

$NGNE chart looks great. Building higher lows.

0 · Reply

Djohn2012 Mar. 3 at 6:17 PM

$NGNE 100% owned by institutions. Baker Bros holding approximately 1 million shares per Yahoo Finance. Baker Bros are the best!

0 · Reply

Fixer00 Mar. 3 at 6:06 PM

$NGNE and gme is good for the portfolio.

1 · Reply

thefourpercent Mar. 3 at 2:50 PM

$NGNE just a bloody day for the market expectations are still the same here

0 · Reply

thefourpercent Mar. 2 at 8:02 PM

$NGNE holy gold mine of a swing trade AND investment here

0 · Reply

RustyNail911 Feb. 27 at 7:41 PM

$NGNE 200$ Price Target & People Are Selling This Low, Make It Make Sense... 🤦‍♂️

1 · Reply

Panama73 Feb. 27 at 7:08 PM

$CDIO Also like $NGNE

0 · Reply

Panama73 Feb. 27 at 6:39 PM

$NGNE Canaccord just announced a buy rating and $200 price target.

0 · Reply

topstockalerts Feb. 27 at 6:32 PM

$NGNE Looks primed for another leg higher. Buyers are still pressing. This trend may not be done yet.

0 · Reply

RoyalHalo Feb. 27 at 6:02 PM

/ @SqueezeSharkie is operating at a level that clearly sets him apart from most traders in this space. If you’re serious about improving your decision-making and refining your edge, he’s worth following. There’s no cost, just consistent insights backed by performance. $NGNE $ALOY $BNAI $BATL <> on close watch.

0 · Reply

topstockalerts Feb. 27 at 5:22 PM

$NGNE Is it going higher?? Comment below

0 · Reply

GSP Feb. 27 at 5:16 PM

Nice move in $NGNE today. .

0 · Reply

Godwins26 Feb. 27 at 4:43 PM

Watchlist today 😊 $JEM $KORE $AAOI $NGNE $EDSA

0 · Reply

topstockalerts Feb. 27 at 4:17 PM

Top Gainers PT2 $XYZG $JEM $VEEA $NGNE $FMFC

0 · Reply

topstockalerts Feb. 27 at 3:14 PM

$NGNE Pulled back into prior breakout zone while insiders continue holding per latest ownership data. Any clinical or regulatory update becomes the spark. Risk is known, catalyst window is defined.

0 · Reply

StockElementCorporation Feb. 27 at 1:55 PM

Premarket movers 📈 Upside: $KORE +80% — acquired at $9.25 cash $XYZ +19% — 40% workforce cut; earnings $PRAA +18% — earnings $AAOI +17% — earnings; up to $250M offering $NGNE +17% — FDA Breakthrough designation ARLO +16% — earnings FIGS +16% — earnings DELL +15% — earnings CAI +14% — earnings MARA +12% — earnings NATL +12% — $6.6B buyout by Brink’s; earnings REAL +12% — earnings PUBM +11% — earnings NFLX +8.0% — PSKY/WBD bid update PSKY +6.7% — WBD bid outcome STRZ +4.2% — earnings Downside: DUOL -26% — earnings; buyback authorized

0 · Reply

mikesterz7 Feb. 27 at 1:53 PM

$NGNE The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

0 · Reply

TheDizPlinTrader Feb. 27 at 1:44 PM

$NGNE 🧬 1 Hour Levels Price: $23.00 Support: $21.40 Resistance: $23.90 👉 Tap follow to keep these 1-hour levels on your feed.

0 · Reply

marycha Feb. 27 at 1:38 PM

$NGNE Nice dippp. Price targets?

0 · Reply

Market Cap	326.53M
Revenue (ttm)	930,000.00
Net Income (ttm)	-75.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-8,079.57%
Debt to Equity Ratio	0.00

Volume	169,200
Avg Vol	168,606
Day's Range	N/A - N/A
Shares Out	15.49M
Stochastic %K	8%
Beta	1.53
Analysts	Strong Sell
Price Target	$81.00